Nutrition & Lifestyle
    Retatrutide

    What to Eat When Retatrutide Kills Appetite

    What to eat when retatrutide kills your appetite is one of the most practical challenges of GLP-1 treatment. The triple-agonist mechanism suppresses hunger so effectively that many patients struggle to eat enough, not too much (Jastreboff et al., NEJM 2023). While reduced appetite drives weight loss, eating too little risks dangerous muscle loss, nutritional deficiencies, and metabolic problems. This guide provides strategies for meeting minimum nutritional needs on your lowest-appetite days.

    Published: April 3, 202611 min read

    The irony of modern weight loss treatment is that the challenge shifts from "how do I stop eating so much?" to "how do I eat enough?" GLP-1 medications can suppress appetite so profoundly that patients go entire days eating only a few hundred calories. While this produces rapid weight loss, it also accelerates muscle catabolism, depletes essential nutrients, and can trigger gallstone formation, hair loss, and metabolic dysfunction. Learning to eat strategically on low-appetite days is a skill that directly impacts the quality -- not just the quantity -- of your weight loss.

    Important Health Notice

    Retatrutide is not FDA-approved for any indication. If you consistently cannot eat at minimum 800 calories or 60g protein daily, contact your healthcare provider -- dose reduction may be needed. Compounded semaglutide ($99/mo) and tirzepatide ($125/mo) are available with medical supervision.

    Minimum Nutritional Targets

    Even on your worst appetite days, strive for at minimum 60g protein (absolute minimum to slow muscle loss), 800-1000 calories (below this, metabolic and gallbladder risks increase), 64 oz fluids (water, broth, herbal tea), and a multivitamin plus any prescribed supplements.

    Easiest Foods When Appetite Is Gone

    Liquids and Semi-Liquids (Often Best Tolerated)

    • Protein shake: 25-30g protein in a drinkable form -- often the easiest option
    • Bone broth: 10g protein per cup, soothing on the stomach, provides electrolytes
    • Greek yogurt: 15-20g protein, smooth texture, easy to eat in small amounts
    • Protein smoothie: Blend protein powder with banana, spinach, and nut butter for 30g+ protein

    Soft Solids (Next Best)

    • Scrambled eggs: 12g protein per 2 eggs, soft and mild
    • Cottage cheese: 14g protein per 1/2 cup
    • Mashed avocado on toast: Add an egg for protein
    • Soft fish (salmon, cod): 20-25g protein, flakes easily

    Snack-Size Protein Bites

    • String cheese: 7g protein, portable
    • Turkey or beef jerky: 10-15g protein per serving
    • Hard-boiled egg: 6g protein, pre-made
    • Protein bar: 15-20g protein, convenient backup

    Practical Strategies

    • Set meal reminders: Without hunger cues, you need external prompts to eat
    • Keep protein snacks visible and accessible: On the counter, in your bag, at your desk
    • Eat first thing in the morning: Appetite is often slightly better before medication effects peak
    • Take a few bites frequently: 6-8 small eating moments per day can add up to adequate nutrition
    • Do not skip protein: If you eat only one thing, make it protein

    When to Contact Your Doctor

    Reach out if you are consistently eating less than 800 calories daily for more than a few days, unable to keep any food or fluids down, experiencing weakness, dizziness, or fainting, noticing significant hair loss, or losing more than 4-5 pounds per week consistently. These may indicate that your dose is too high and adjustment is needed.

    Medical Disclaimer

    This article is for informational purposes only and does not constitute medical advice. Retatrutide is not FDA-approved for any indication. Severe appetite loss that prevents adequate nutrition requires medical evaluation and potential dose adjustment. Consult your healthcare provider if you cannot meet minimum nutritional targets.

    Expert-Supervised Weight Loss

    Compounded semaglutide from $99/mo. Compounded tirzepatide from $125/mo. Personalized dosing to balance results and nutrition.

    View Treatment Options

    Sources & References

    1. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. NEJM 2021;384:989-1002.
    2. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. NEJM 2022;387:205-216.
    3. Lincoff AM et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. NEJM 2023;389:2221-2232.
    4. FDA Prescribing Information for Wegovy (semaglutide) and Zepbound (tirzepatide).

    What does the published clinical evidence show for retatrutide?

    Peer-reviewed evidence: Retatrutide 12 mg produced a mean body weight reduction of approximately 24.2% at 48 weeks in adults with obesity in a Phase 2 trial — the highest published mean weight reduction for any GLP-1-class agent in obesity to date. (Source: Jastreboff et al. Phase 2 trial, NEJM 2023). Trimi is preparing for launch; compounded availability depends on FDA-cleared compounding pathways. Results vary by individual; eligibility is determined by a licensed clinician.

    Retatrutide 12 mg produced a mean body weight reduction of approximately 24.2% at 48 weeks in adults with obesity in a Phase 2 trial — the highest published mean weight reduction for any GLP-1-class agent in obesity to date. — Jastreboff et al. Phase 2 trial, NEJM 2023
    Retatrutide 12 mg reduced HbA1c by approximately 2.02 percentage points at 36 weeks in patients with type 2 diabetes, compared with 1.41 points on dulaglutide 1.5 mg. — Rosenstock et al. Phase 2 T2D trial, Lancet 2023

    Key Takeaways

    • Retatrutide 12 mg produced a mean body weight reduction of approximately 24.2% at 48 weeks in adults with obesity in a Phase 2 trial — the highest published mean weight reduction for any GLP-1-class agent in obesity to date. (Source: Jastreboff et al. Phase 2 trial, NEJM 2023)
    • Retatrutide 12 mg reduced HbA1c by approximately 2.02 percentage points at 36 weeks in patients with type 2 diabetes, compared with 1.41 points on dulaglutide 1.5 mg. (Source: Rosenstock et al. Phase 2 T2D trial, Lancet 2023)
    • Retatrutide is investigational and not FDA-approved as of publication. Trial findings reported here are from Phase 2 / Phase 3 studies in peer-reviewed sources cited below.
    • Eligibility requires evaluation by a licensed clinician: BMI ≥30, or BMI ≥27 with at least one weight-related comorbidity (type 2 diabetes, hypertension, dyslipidemia, obstructive sleep apnea, cardiovascular disease). Contraindications include personal or family history of medullary thyroid carcinoma, MEN 2 syndrome, pancreatitis, severe gastrointestinal disease, severe renal impairment, pregnancy, and breastfeeding.
    • Common GLP-1 receptor agonist adverse effects include nausea, vomiting, diarrhea, constipation, and gallbladder events. Dose titration over weeks improves tolerability. Severe gastrointestinal symptoms may cause dehydration and increase acute kidney injury risk.
    • This is general information based on the cited evidence, not medical advice. Treatment decisions require evaluation by a licensed clinician familiar with your individual medical history, BMI, and comorbidities.

    Medically Reviewed

    TMRT

    Trimi Medical Review Team

    Clinical review workflow for GLP-1 safety, dosing, and access content

    Team-based medical review process documented in Trimi's Medical Review Policy

    Last reviewed: May 18, 2026

    TCCT

    Written by Trimi Clinical Content Team

    Medical Writers & Healthcare Professionals

    Our clinical content team includes registered nurses, pharmacists, and medical writers who specialize in translating complex medical information into clear, actionable guidance for patients.

    Medically reviewed by Trimi Medical Review Team, Clinical review workflow for GLP-1 safety, dosing, and access content

    What real Trimi patients say

    Verbatim quotes from Trimi's Facebook and Reddit community reviews. First name and last initial preserved per editorial policy.

    Really great customer service! Fast shipment.

    Outcome: Fast shipment

    Amy KeithFacebook
    I'm on my 4th week. No side effects. 5 lb loss which seems slow to me. Food noise is much better. We shall see!

    Outcome: 5 lbs lost in 4 weeks; no side effects; food noise reduced

    Lynn SchweitzerFacebook

    Editorial Standards

    Trimi publishes patient education using a medical-review workflow, source-based claim checks, and dated updates for fast-changing pricing, access, and safety topics.

    Review our Editorial Policy and Medical Review Policy for more details about sourcing, updates, and reviewer attribution.

    Scientific References

    1. Jastreboff AM, Kaplan LM, Frías JP, et al. (2023). Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. New England Journal of Medicine.Read StudyDOI: 10.1056/NEJMoa2301972
    2. Rosenstock J, Frias J, Jastreboff AM, et al. (2023). Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial. The Lancet.Read StudyDOI: 10.1016/S0140-6736(23)01053-X
    3. ClinicalTrials.gov (2024). A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Are Overweight (TRIUMPH-1) — NCT05929066. ClinicalTrials.gov.Read Study
    4. Garvey WT, Mechanick JI, Brett EM, et al. (2024). American Association of Clinical Endocrinology / American College of Endocrinology Comprehensive Clinical Practice Guidelines for Medical Care of Patients with Obesity. Endocrine Practice.Read StudyDOI: 10.4158/EP161365.GL
    5. American Heart Association (2021). Obesity and Cardiovascular Disease: A Scientific Statement From the American Heart Association. Circulation.Read StudyDOI: 10.1161/CIR.0000000000000973
    6. Apovian CM, Aronne LJ, Bessesen DH, et al. (2015). Pharmacological Management of Obesity: An Endocrine Society Clinical Practice Guideline. Journal of Clinical Endocrinology & Metabolism.Read StudyDOI: 10.1210/jc.2014-3415

    Was this article helpful?

    Keep Reading

    Detailed comparison of retatrutide vs orforglipron: injectable triple agonist vs the first oral GLP-1 pill. Weight loss data, convenience, side effects, and which might be right for you.

    FDA approved oral Wegovy (semaglutide 50mg tablet) for weight loss in 2026. Review covers clinical trial results (~15% body weight loss), dosing, side effects, cost ($1,000–$1,500/mo), and affordable injectable alternatives.

    Detailed comparison of retatrutide vs tirzepatide: 24.2% vs 22.5% weight loss, mechanism differences, side effects, cost projections, and whether to wait or start now.

    Complete guide covering finding the best online weight loss doctors in 2026. Compare options, understand pricing, and discover how compounded GLP-1 medications deliver the same active ingredients at u

    Start your GLP-1 journey — from $99/mo

    Get Started